GSK, Hitachi Chemical in T-Cell Manufacturing Pact
The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.
GSK and Hitachi Chemical Advanced Therapeutics Solutions (HCATS), a US subsidiary of Hitachi Chemical, announced that they have signed a three-year clinical manufacturing agreement on Oct. 1, 2018.
Under the agreement, HCATS will manufacture GSK’s specific peptide enhanced affinity receptor T-cell receptor (SPEAR) therapy for United States, Canadian and European trials. GSK’s SPEAR T-cell receptor therapy is an investigational cancer immunotherapy being developed by GSK and Adaptimmune, an Oxfordshire, UK-based T-cell therapy company, that targets NY-ESO-1. The targeted receptor is expressed across a variety of tumors including sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer, and gastro-intestinal cancers.
HCATS is focused on the contract manufacturing and development of cell-based cell and gene therapy products through its PCT Global Service Platform.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
